{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:52:36Z","timestamp":1791273156643,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"DOI":"10.1007\/s00108-026-02150-0","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:20:44Z","timestamp":1791271244000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Personalisierte Arzneimitteltherapie des metastasierten Lungenkarzinoms","Personalized drug therapy of metastatic lung cancer"],"prefix":"10.1007","author":[{"given":"Sofia","family":"Stilianakis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Ruge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Scharpenseel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malte","family":"Verheyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,6]]},"reference":[{"key":"2150_CR1","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s40265-025-02276-9","volume":"86","author":"P Abdayem","year":"2026","unstructured":"Abdayem\u00a0P, Parisi\u00a0C, Planchard\u00a0D (2026) First Line and Treatment Sequencing in EGFR-Mutated Metastatic NSCLC: What is Right for Which Patient? Drugs 86:335\u2013357. https:\/\/doi.org\/10.1007\/s40265-025-02276-9","journal-title":"Drugs"},{"key":"2150_CR2","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/s41417-026-01003-0","volume":"33","author":"D Bhattacharya","year":"2026","unstructured":"Bhattacharya\u00a0D, Roman\u00a0B, Reddy\u00a0S (2026) Therapeutic advances with KRASG12C inhibitors and combination strategies in non-small cell lung cancer brain metastases. Cancer Gene Ther 33:323\u2013337. https:\/\/doi.org\/10.1038\/s41417-026-01003-0","journal-title":"Cancer Gene Ther"},{"key":"2150_CR3","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.jtho.2023.12.015","volume":"19","author":"P Bischoff","year":"2024","unstructured":"Bischoff\u00a0P, Reck\u00a0M, Overbeck\u00a0T et\u00a0al (2024) Outcome of First-Line Treatment With Pembrolizumab According to KRAS\/TP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1\u2013High (\u2265 50 %) NSCLC in the German National Network Genomic Medicine Lung Cancer. JTO Clin Res Rep 19:803\u2013817. https:\/\/doi.org\/10.1016\/j.jtho.2023.12.015","journal-title":"Journal of Thoracic Oncology"},{"key":"2150_CR4","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1007\/s00292-019-0605-4","volume":"40","author":"R B\u00fcttner","year":"2019","unstructured":"B\u00fcttner\u00a0R, Wolf\u00a0J, Kron\u00a0A, Nationales Netzwerk Genomische Medizin (2019) Das nationale Netzwerk Genomische Medizin (nNGM). Pathologie 40:276\u2013280. https:\/\/doi.org\/10.1007\/s00292-019-0605-4","journal-title":"Pathologe"},{"key":"2150_CR5","doi-asserted-by":"publisher","first-page":"8538","DOI":"10.1200\/JCO.2025.43.16_suppl.8538","volume":"43","author":"N Dahake","year":"2025","unstructured":"Dahake\u00a0N, Baca\u00a0Y, Serebriiskii\u00a0I et\u00a0al (2025) Clinical outcomes and characterization of HER2 alterations in non-small cell lung cancer (NSCLC). J\u00a0Clin Oncol 43:8538\u20138538. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.8538","journal-title":"JCO"},{"key":"2150_CR6","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/S0140-6736(23)00221-0","volume":"401","author":"AJ De Langen","year":"2023","unstructured":"De Langen\u00a0AJ, Johnson\u00a0ML, Mazieres\u00a0J et\u00a0al (2023) Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial. The Lancet 401:733\u2013746. https:\/\/doi.org\/10.1016\/S0140-6736(23)00221-0","journal-title":"The Lancet"},{"issue":"Suppl 1","key":"2150_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35784","volume":"131","author":"A Desilets","year":"2025","unstructured":"Desilets\u00a0A, Repetto\u00a0M, Yang\u00a0SR, Drilon\u00a0A (2025) Targeting ROS1 rearrangements in non-small cell lung cancer: Current insights and future directions. Cancer Cytopathol 131(Suppl 1):e35784. https:\/\/doi.org\/10.1002\/cncr.35784","journal-title":"Cancer"},{"key":"2150_CR8","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1056\/NEJMoa2302299","volume":"390","author":"A Drilon","year":"2024","unstructured":"Drilon\u00a0A, Camidge\u00a0DR, Lin\u00a0JJ et\u00a0al (2024) Repotrectinib in ROS1 Fusion-Positive Non-Small Cell Lung Cancer. N Engl J Med 390:118\u2013131. https:\/\/doi.org\/10.1056\/NEJMoa2302299","journal-title":"N Engl J Med"},{"key":"2150_CR9","doi-asserted-by":"publisher","unstructured":"Heymach\u00a0JV, Yamamoto\u00a0N, Girard\u00a0N et\u00a0al First-Line Zongertinib in Advanced HER2-Mutant Non\u2013Small-Cell Lung Cancer. New England Journal of Medicine. https:\/\/doi.org\/10.1056\/NEJMoa2516969","DOI":"10.1056\/NEJMoa2516969"},{"key":"2150_CR10","doi-asserted-by":"publisher","unstructured":"Illini\u00a0O, Hund\u00a0AC, Kopp\u00a0HG et\u00a0al (2026) Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in Patients with HER2-Mutant Non-Small Cell Lung Cancer across Treatment Lines: Evidence from the TRACER\/HERTras Real-World Cohort. JTO Clin Res Rep103651. https:\/\/doi.org\/10.1016\/j.jtho.2026.103651","DOI":"10.1016\/j.jtho.2026.103651"},{"key":"2150_CR11","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1016\/j.jtho.2025.07.129","volume":"20","author":"PA J\u00e4nne","year":"2025","unstructured":"J\u00e4nne\u00a0PA, Goto\u00a0Y, Kubo\u00a0T et\u00a0al (2025) Final Analysis Results and Patient-Reported Outcomes From DESTINY-Lung02\u2014A Dose-Blinded, Randomized, Phase 2 Study of Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic NSCLC. JTO Clin Res Rep 20:1814\u20131828. https:\/\/doi.org\/10.1016\/j.jtho.2025.07.129","journal-title":"Journal of Thoracic Oncology"},{"key":"2150_CR12","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1056\/NEJMoa2510308","volume":"394","author":"PA J\u00e4nne","year":"2025","unstructured":"J\u00e4nne\u00a0PA, Planchard\u00a0D, Kobayashi\u00a0K et\u00a0al (2025) Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC. New England Journal of Medicine 394:27\u201338. https:\/\/doi.org\/10.1056\/NEJMoa2510308","journal-title":"New England Journal of Medicine"},{"key":"2150_CR13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-25-2581","author":"F John","year":"2025","unstructured":"John\u00a0F, Ruge\u00a0L, Verheyen\u00a0M et\u00a0al (2025) Molecular and clinical characteristics of patients with non-small cell lung cancer (NSCLC) harboring KRAS G12V mutations. Clin Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-25-2581","journal-title":"Clin Cancer Res"},{"key":"2150_CR14","doi-asserted-by":"publisher","first-page":"3706","DOI":"10.1200\/JCO-25-02023","volume":"43","author":"ML Johnson","year":"2025","unstructured":"Johnson\u00a0ML, Smit\u00a0EF, Felip\u00a0E et\u00a0al (2025) Updated Overall Survival Analysis From the Phase II PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non\u2013Small Cell Lung Cancer. J\u00a0Clin Oncol 43:3706\u20133713. https:\/\/doi.org\/10.1200\/JCO-25-02023","journal-title":"J Clin Oncol"},{"key":"2150_CR15","doi-asserted-by":"publisher","unstructured":"Krause\u00a0DS, Etten\u00a0RAV Tyrosine Kinases as Targets for Cancer Therapy. New England Journal of Medicine 353:172\u2013187. https:\/\/doi.org\/10.1056\/NEJMra044389","DOI":"10.1056\/NEJMra044389"},{"key":"2150_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105124","author":"C Kropf-Sanchen","year":"2025","unstructured":"Kropf-Sanchen\u00a0C, Rasokat\u00a0A, Christopoulos\u00a0P et\u00a0al (2025) Treatment outcome of NSCLC patients with BRAFnon-V600E mutations: a retrospective, multicentre analysis within the national Network Genomic Medicine (nNGM) Lung Cancer in Germany. ESMO Open. https:\/\/doi.org\/10.1016\/j.esmoop.2025.105124","journal-title":"ESMO Open"},{"key":"2150_CR17","doi-asserted-by":"publisher","first-page":"75","DOI":"10.2147\/LCTT.S460147","volume":"15","author":"ATM Lee","year":"2024","unstructured":"Lee\u00a0ATM, Ou\u00a0SHI (2024) LIBRETTO-431: Confirming the Superiority of Selpercatinib to Chemotherapy and the Lack of Efficacy of Immune Checkpoint Inhibitors in Advanced RET Fusion-Positive (RET+) NSCLC, Another Unique Never-Smoker Predominant Molecular Subtype of NSCLC. Lung Cancer (Auckl) 15:75\u201380. https:\/\/doi.org\/10.2147\/LCTT.S460147","journal-title":"Lung Cancer (Auckl)"},{"key":"2150_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2023.107282","volume":"182","author":"Z Lin","year":"2023","unstructured":"Lin\u00a0Z, Li\u00a0Y, Tang\u00a0S et\u00a0al (2023) Comparative analysis of genomic profiles between tissue-based and plasma-based next-generation sequencing in patients with non-small cell lung cancer. Lung Cancer 182:107282. https:\/\/doi.org\/10.1016\/j.lungcan.2023.107282","journal-title":"Lung Cancer"},{"key":"2150_CR19","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/s41571-023-00844-0","volume":"21","author":"J LoPiccolo","year":"2024","unstructured":"LoPiccolo\u00a0J, Gusev\u00a0A, Christiani\u00a0DC, J\u00e4nne\u00a0PA (2024) Lung cancer in patients who have never smoked \u2014 an emerging disease. Nat Rev Clin Oncol 21:121\u2013146. https:\/\/doi.org\/10.1038\/s41571-023-00844-0","journal-title":"Nat Rev Clin Oncol"},{"key":"2150_CR20","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1038\/s41591-025-03600-2","volume":"31","author":"Y Ma","year":"2025","unstructured":"Ma\u00a0Y, Yang\u00a0Y, Huang\u00a0Y et\u00a0al (2025) A B7H3-targeting antibody\u2013drug conjugate in advanced solid tumors: a phase 1\/1b trial. Nat Med 31:1949\u20131957. https:\/\/doi.org\/10.1038\/s41591-025-03600-2","journal-title":"Nat Med"},{"key":"2150_CR21","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S0140-6736(24)01029-8","volume":"404","author":"ML Meyer","year":"2024","unstructured":"Meyer\u00a0ML, Fitzgerald\u00a0BG, Paz-Ares\u00a0L et\u00a0al (2024) New promises and challenges in the treatment of advanced non-small-cell lung cancer. The Lancet 404:803\u2013822. https:\/\/doi.org\/10.1016\/S0140-6736(24)01029-8","journal-title":"The Lancet"},{"key":"2150_CR22","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","volume":"393","author":"TSK Mok","year":"2019","unstructured":"Mok\u00a0TSK, Wu\u00a0YL, Kudaba\u00a0I et\u00a0al (2019) Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a\u00a0randomised, open-label, controlled, phase\u00a03\u00a0trial. The Lancet 393:1819\u20131830. https:\/\/doi.org\/10.1016\/S0140-6736(18)32409-7","journal-title":"The Lancet"},{"key":"2150_CR23","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1056\/NEJMoa2502099","volume":"393","author":"G Mountzios","year":"2025","unstructured":"Mountzios\u00a0G, Sun\u00a0L, Cho\u00a0BC et\u00a0al (2025) Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy. New England Journal of Medicine 393:349\u2013361. https:\/\/doi.org\/10.1056\/NEJMoa2502099","journal-title":"New England Journal of Medicine"},{"key":"2150_CR24","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1056\/NEJMoa2004407","volume":"383","author":"PK Paik","year":"2020","unstructured":"Paik\u00a0PK, Felip\u00a0E, Veillon\u00a0R et\u00a0al (2020) Tepotinib in Non\u2013Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. New England Journal of Medicine 383:931\u2013943. https:\/\/doi.org\/10.1056\/NEJMoa2004407","journal-title":"New England Journal of Medicine"},{"key":"2150_CR25","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1016\/S1470-2045(17)30679-4","volume":"18","author":"D Planchard","year":"2017","unstructured":"Planchard\u00a0D, Smit\u00a0EF, Groen\u00a0HJM et\u00a0al (2017) Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. The Lancet Oncology 18:1307\u20131316. https:\/\/doi.org\/10.1016\/S1470-2045(17)30679-4","journal-title":"The Lancet Oncology"},{"key":"2150_CR26","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","volume":"382","author":"SS Ramalingam","year":"2020","unstructured":"Ramalingam\u00a0SS, Vansteenkiste\u00a0J, Planchard\u00a0D et\u00a0al (2020) Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC. N Engl J Med 382:41\u201350. https:\/\/doi.org\/10.1056\/NEJMoa1913662","journal-title":"N Engl J Med"},{"key":"2150_CR27","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.jtho.2018.12.013","volume":"14","author":"M Scheffler","year":"2019","unstructured":"Scheffler\u00a0M, Ihle\u00a0MA, Hein\u00a0R et\u00a0al (2019) K\u2011ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways. JTO Clin Res Rep 14:606\u2013616. https:\/\/doi.org\/10.1016\/j.jtho.2018.12.013","journal-title":"Journal of Thoracic Oncology"},{"key":"2150_CR28","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1056\/NEJMoa011954","volume":"346","author":"JH Schiller","year":"2002","unstructured":"Schiller\u00a0JH, Harrington\u00a0D, Belani\u00a0CP et\u00a0al (2002) Comparison of Four Chemotherapy Regimens for Advanced Non\u2013Small-Cell Lung Cancer. New England Journal of Medicine 346:92\u201398. https:\/\/doi.org\/10.1056\/NEJMoa011954","journal-title":"New England Journal of Medicine"},{"key":"2150_CR29","unstructured":"Shanghai YingLi Pharmaceutical Co. Ltd. (2025) A Multi-Center, Open-Label, Phase\u00a0I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS. clinicaltrials.gov"},{"key":"2150_CR30","doi-asserted-by":"publisher","first-page":"3931","DOI":"10.1158\/0008-5472.CAN-17-0299","volume":"77","author":"SK Sharma","year":"2017","unstructured":"Sharma\u00a0SK, Pourat\u00a0J, Abdel-Atti\u00a0D et\u00a0al (2017) Noninvasive Interrogation of DLL3 Expression in Metastatic Small Cell Lung Cancer. Cancer Res 77:3931\u20133941. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-0299","journal-title":"Cancer Res"},{"key":"2150_CR31","doi-asserted-by":"publisher","first-page":"3400","DOI":"10.1200\/JCO.24.00581","volume":"42","author":"BJ Solomon","year":"2024","unstructured":"Solomon\u00a0BJ, Liu\u00a0G, Felip\u00a0E et\u00a0al (2024) Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non\u2013Small Cell Lung Cancer: 5\u2011Year Outcomes From the Phase III CROWN Study. J\u00a0Clin Oncol 42:3400\u20133409. https:\/\/doi.org\/10.1200\/JCO.24.00581","journal-title":"JCO"},{"key":"2150_CR32","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1093\/oncolo\/oyae022","volume":"29","author":"T Stricker","year":"2024","unstructured":"Stricker\u00a0T, Jain\u00a0N, Ma\u00a0E et\u00a0al (2024) Clinical Value of Timely Targeted Therapy for Patients With Advanced Non\u2013Small Cell Lung Cancer With Actionable Driver Oncogenes. Oncologist 29:534\u2013542. https:\/\/doi.org\/10.1093\/oncolo\/oyae022","journal-title":"Oncologist"},{"key":"2150_CR33","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1056\/NEJMoa2503001","volume":"393","author":"JCH Yang","year":"2025","unstructured":"Yang\u00a0JCH, Lu\u00a0S, Hayashi\u00a0H et\u00a0al (2025) Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC. N Engl J Med 393:1681\u20131693. https:\/\/doi.org\/10.1056\/NEJMoa2503001","journal-title":"N Engl J Med"},{"key":"2150_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1241402","volume":"13","author":"M Yang","year":"2024","unstructured":"Yang\u00a0M, Mandal\u00a0E, Liu\u00a0FX et\u00a0al (2024) Non-small cell lung cancer with MET amplification: review of epidemiology, associated disease characteristics, testing procedures, burden, and treatments. Front Oncol 13:1241402. https:\/\/doi.org\/10.3389\/fonc.2023.1241402","journal-title":"Front Oncol"},{"key":"2150_CR35","doi-asserted-by":"crossref","unstructured":"Zhou C, Tang K\u2011J, Cho BC et\u00a0al. (2023) Amivantamab plus Chemotherapy in NSCLC with EGFR Exon\u00a020 Insertions. N Engl J Med 389:2039\u20132051. https:\/\/doi.org\/10.1056\/NEJMoa2306441.","DOI":"10.1056\/NEJMoa2306441"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-026-02150-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-026-02150-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-026-02150-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:20:45Z","timestamp":1791271245000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-026-02150-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,6]]},"references-count":35,"alternative-id":["2150"],"URL":"https:\/\/doi.org\/10.1007\/s00108-026-02150-0","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"value":"2731-7080","type":"print"},{"value":"2731-7099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,6]]},"assertion":[{"value":"8 June 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.\u00a0Stilianakis: Reisekostenerstattung\/Kongressgeb\u00fchren: Johnson & Johnson, Pierre Fabre. H.\u00a0Scharpenseel: Reisekostenerstattung: Johnson & Johnson, Tubulis. L.\u00a0Ruge: Beratungst\u00e4tigkeit: BeOne, Johnson & Johnson, Amgen; Reisekostenerstattung\/Kongressgeb\u00fchren: Daiichi Sankyo, Amgen, Johnson & Johnson, M.\u00a0Verheyen: Reisekostenerstattung\/Kongressgeb\u00fchren: BeiGene, Lilly, Johnson & Johnson, BeOne; Vortragshonorare: Pfizer, Johnson & Johnson, Bristol-Myers Squibb, AbbVie, BeiGene, Stemline, BeOne. Wissenschaftlicher Beirat: BeOne. J.\u00a0Wolf: Honorare: AbbVie; Amgen; Amgen Astellas BioPharma; AstraZeneca; Bayer; BeiGene; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; DISCO Pharmaceuticals; Ellipses Pharma; Genmab; Janssen; Kingyee Beiging Co. LTD.; Lilly; Merck; Mirati Therapeutics; MSD; Novartis; Nuvalent, Inc.; Nuvation Bio; Pfizer; Regeneron; Revolution Medicines; Roche; Seagen; Takeda; Turning Point Therapeutics; Zuelling Pharma. Beratungst\u00e4tigkeit: AbbVie; Amgen; AstraZeneca; Bayer; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; Ignyta; Janssen; Lilly; Loxo\/Lilly; Merck; Mirati Therapeutics; Novartis; Nuvalent, Inc.; Pfizer; Roche; Seagen; Takeda. Forschungsunterst\u00fctzung: AstraZeneca; Bristol-Myers Squibb; Janssen; Novartis; Pfizer. Reisekostenerstattung: Amgen; AstraZeneca; Intellisphere; Janssen; Merck; Mirati Therapeutics; Novartis; Pfizer; Sanofi.","order":1,"name":"Ethics","label":"Interessenkonflikt","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}}]}}